Analysts have been eager to weigh in on the Healthcare sector with new ratings on Dexcom (DXCM – Research Report) and Amgen (AMGN – Research ...

Morgan Stanley analyst Terence Flynn raised the firm’s price target on Amgen (AMGN) to $330 from $328 and keeps an Equal Weight rating on the ...

With a label expansion for Uplizna pushing the drug into an untouched rare disease market, Amgen is getting its money’s worth out of another drug from its $27.8 billion Horizon Therapeutics buy.

Investing.com -- Shares of Amgen Inc (NASDAQ:AMGN) climbed 1.4% today after the company announced that the U.S. Food and Drug Administration (FDA) has approved its drug UPLIZNA for the treatment ...

The case had been filed last year by Amgen after the state Prescription Drug Affordability Board determined that its big-selling medication called Enbrel is unaffordable and began a process to ...

Just today, Amgen (AMGN) announced updated Uplizna results showing a deepening of responses six months after a single repeat infusion, Opco points out. It believes extrapolating from Cartesian’s ...

April 3 (Reuters) - The U.S. Food and Drug Administration has approved expanded use of Amgen's (AMGN.O), opens new tab drug, Uplizna, to help reduce the risk of flares in patients with a rare ...

(Reuters) -The U.S. Food and Drug Administration has approved expanded use of Amgen's drug, Uplizna, to help reduce the risk of flares in patients with a rare immune system-related condition ...

Amgen will now move ahead with a phase 2 programme for AMG 133, as it tries to enter a weight-loss category that has been transformed by the approval of Novo Nordisk’s once-weekly GLP-1 agonist ...

Amgen is planning to push its olpasiran candidate for reducing lipoprotein(a) into phase 3 as quickly as possible as it tries to catch up with rival programmes at Novartis. The US biotech has just ...